Treace Medical Concepts (TMCI) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic direction and market positioning

• Expanded from a single Lapiplasty technology to a comprehensive 3D bunion solutions portfolio, targeting all four classes of bunion deformities with advanced systems.

• Now serves over 3,300 surgeon customers, achieving a 21% CAGR in surgeon user growth over five years and nearly 8% market penetration in 2025.

• Focused on increasing wallet share by addressing the remaining 75% of customers' bunion-related cases with new technologies.

• Maintains a direct sales force for about 70-75% of revenue, with targeted expansion in key territories and ongoing recruitment of experienced reps.

• Strategy includes adding complementary technologies and expanding into adjacent procedures to further penetrate the $5B+ U.S. bunion market.

Product innovation and clinical outcomes

• Launched Nanoplasty and Percuplasty 3D MIS systems, Speed MTP, and Micro-Lapiplasty, targeting high-volume osteotomy and MTP fusion segments.

• Lapiplasty Lightning, a next-generation platform, aims for faster, more accurate procedures and broader surgeon appeal, with full commercialization expected by end of 2026.

• Peer-reviewed four-year interim results from the ALIGN3D study showed 81% pain reduction and low recurrence rates at 48 months, reinforcing Lapiplasty as the gold standard.

• IntelliGuide PSI platform offers personalized, preoperative planning and patient-specific cut guides for complex cases.

• New biologics and fixation products, such as Percuplasty SuperBite, are being added to support core procedures.

Market trends, opportunity, and adoption

• Estimated 67 million US adults affected by bunions, with 4.4 million seeking treatment annually and 1.1 million surgical candidates.

• Bunion market remains under-penetrated, with only half of surgical candidates opting for surgery due to concerns over pain and recovery.

• Surgeons are rapidly adopting new MIS technologies, with hundreds of first-time users enabled in 2025 and strong positive feedback.

• MIS procedures currently represent 10-15% of osteotomies but are expected to grow as learning curves decrease and outcomes improve.

• 56% of bunion patients would be more interested in surgery if offered a minimally invasive option.